This page is educational and not medical advice. It covers what the test measures, how results are reported, what a low value may reflect, why timing changes the answer, and which markers are worth running at the same time.
It measures enzyme function, not just the presence of a gene. A laboratory takes a blood sample, supplies the enzyme with its substrate, and measures how fast the red cells generate NADPH, the molecule that keeps the cell's antioxidant defences topped up. The faster that reaction runs, the more enzyme activity is present. The result is then compared against the reference interval for that laboratory and that method.
There are two broad formats. A qualitative screen sorts samples into normal or deficient without producing a number, which is useful when the question is simply whether a deficiency exists. A quantitative assay produces an actual activity value, which lets a clinician see how much function is left rather than only whether some is missing. Both are commonly ordered under the same everyday names, including G6PD blood test, G6PD enzyme activity and G6PD screen.
It helps to be clear about what the measurement does not do. It does not count red blood cells, does not tell you whether anemia is present right now, and does not predict exactly how a person will respond to a given exposure. Research suggests that glucose-6-phosphate dehydrogenase deficiency is the most common enzyme disorder of red blood cells worldwide, which is part of why the test is ordered so often in people with unexplained red cell breakdown 1.
The useful way to read a result is in three steps. First, what the value shows, which is the measured enzyme activity. Second, what it may reflect, which is the inherited capacity of your red cells to resist oxidative stress. Third, what is worth doing next, which is a conversation with a clinician about confirming the result and about exposures that matter for you.
Hemoglobin is the oxygen-carrying protein packed inside red blood cells, and it is what the body loses when those cells break apart early. Laboratories commonly report G6PD activity in units per gram of hemoglobin, which is why the two values often appear next to each other on the same report.
In practical terms, the enzyme result describes vulnerability and the hemoglobin result describes consequence. A hemoglobin value that drops after a trigger exposure is one of the signals a clinician watches when deciding whether red cell breakdown has actually occurred. The dedicated Hemoglobin guide covers what the marker is, how it is measured and how to read a value; here, the only point that matters is that it is a downstream marker, not the enzyme measurement itself.
G6PD is the gatekeeper of the only antioxidant pathway a mature red blood cell has. The enzyme runs the first step of the pentose phosphate pathway, which produces NADPH. NADPH in turn keeps glutathione in its reduced, working form, and reduced glutathione neutralises the oxidising compounds that constantly form inside a cell carrying oxygen.
This matters more in red cells than anywhere else in the body. A mature red cell has no nucleus and no mitochondria, so it cannot manufacture replacement enzyme and cannot route around the pathway using another energy system. It leaves the bone marrow with a fixed supply of enzyme, and that supply declines steadily across the cell's lifespan. Older red cells therefore have the least protection, which is why they are usually the first to go during an oxidative challenge.
When defences are overwhelmed, hemoglobin inside the cell oxidises and clumps into deposits called Heinz bodies. The spleen strips those deposits out, leaving the characteristic bite cells and blister cells visible on a blood film, and the damaged cells are removed from circulation. In heavier episodes, cells rupture inside the vessels themselves and free hemoglobin spills into the plasma and the urine. Studies indicate that the variant a person inherits strongly influences how much residual enzyme activity remains and how severely the cells respond to stress 2.
Most laboratories report G6PD activity as a number in units per gram of hemoglobin, with their own reference interval attached, because methods and temperatures differ enough that one laboratory's interval does not transfer to another. Rather than memorising a number, it is more useful to understand the categories a report falls into.
| Category on the report | Roughly what it reflects |
|---|---|
| Normal activity | Activity sits within the laboratory's reference interval for its own method |
| Intermediate activity | Partial reduction, often seen in females carrying one affected copy of the gene |
| Deficient activity | Markedly reduced activity, the usual finding in males carrying an affected copy |
| Indeterminate or borderline | A value too close to the cut-off to classify, usually repeated after recovery from any recent illness |
Studies indicate that variants can be grouped by the residual enzyme activity they leave behind, which supports a revised World Health Organization classification using activity bands such as under 20 percent and under 45 percent of normal, with roughly 60 to 150 percent regarded as normal 3.
Because hemoglobin so often travels with this test, it is worth seeing how a standard laboratory range compares with an optimization target.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Hemoglobin, men | 13 to 17.5 g/dL | 14 to 16 g/dL |
| Hemoglobin, women | 11.5 to 16 g/dL | 12 to 15 g/dL |
Reference ranges vary by laboratory, age and sex, and the ranges above are typical rather than universal. Optimal ranges are optimization targets set by FitScript, not diagnostic cut-offs, and a value outside them is a prompt for a conversation rather than a conclusion.
A low result means the red cells carry less oxidative protection than usual, most often because of an inherited change in the G6PD gene. The gene sits on the X chromosome, so males who inherit an affected copy generally show clearly reduced activity, while females may show deficient, intermediate or near-normal activity depending on which copy is active in which cells. Research suggests that this X-linked pattern, combined with the sheer number of described variants, explains the wide spread of clinical pictures seen in people with the same broad label 1.
A low value is not a statement about how you feel today. Many people with reduced activity go years without any symptom at all, because nothing has stressed the cells hard enough to matter. Studies indicate that red cell breakdown in this condition is usually episodic, appearing after an oxidative trigger and settling once the trigger is removed and the oldest cells have been cleared 4.
A smaller group of variants behaves differently. Evidence suggests that certain severe variants produce ongoing red cell breakdown even without an identifiable trigger, a picture described as chronic non-spherocytic hemolytic anemia 5. Reduced enzyme activity is also one of the recognised contributors to prolonged jaundice detected through newborn screening programmes 5.
One value never establishes a diagnosis on its own. A suboptimal or low enzyme result is a finding to confirm and interpret with a clinician, who will weigh it against your history, your blood count and the circumstances in which the sample was drawn.
Because the most deficient cells have already been destroyed, which leaves the survivors looking better than the population as a whole. During and immediately after red cell breakdown, the bone marrow floods the circulation with young cells and reticulocytes, and young cells carry the highest enzyme activity. Measure the blood at that moment and the average activity can land inside the reference interval even in someone with a genuine deficiency.
Evidence suggests that enzyme assays performed during or shortly after an acute hemolytic episode can therefore read falsely normal, and that repeat testing once the blood count has stabilised gives a more reliable answer 6. This is the single most common reason a result misleads, and it is entirely avoidable with timing.
The same logic applies in reverse to interpretation in females. Because one X chromosome is randomly inactivated in each cell, a heterozygous female carries a mixture of normal and deficient red cells, and the averaged measurement can sit anywhere from clearly deficient to apparently normal while a meaningful fraction of her cells remain vulnerable.
The practical takeaway is simple. If a sample was drawn during an episode, during recovery, or soon after a transfusion, mention that to whoever interprets the result, because the number may need repeating.
Three categories account for most episodes, and each one works by raising the oxidative load inside red cells beyond what the remaining enzyme can handle. Studies indicate that acute hemolysis in people with this deficiency typically follows fava bean ingestion, an infection or exposure to certain oxidising medicines 4.
Fava beans are the classic trigger, and the reaction is distinctive enough that it gave the condition its common name, favism. Eating fava beans is associated with acute red cell breakdown in susceptible people, and research suggests the evidence for avoiding this particular food is stronger than for any other dietary restriction 8.
Infection is the trigger people least expect. Studies indicate that infections are among the most frequent precipitants of hemolysis in this condition, probably because activated immune cells release oxidising compounds as part of the normal response 4. That is why a clinician may pay closer attention to blood counts during a significant illness in someone with a known deficiency.
Some medicines also impose oxidative stress on red cells. Which ones matter, and whether an alternative exists, is a clinical judgement that depends on the variant, the person and the reason the medicine is being considered, so the relevant step is making sure every clinician and pharmacist you deal with knows your G6PD status before anything new is started. No specific medicines are named here on purpose. Treatment decisions belong to a licensed provider, who evaluates whether any given option is appropriate for you.
An acute episode usually announces itself within a day or two of the exposure, and the symptoms come from losing red cells faster than they can be replaced. Common features include sudden fatigue, pallor, breathlessness on mild exertion, a faster heartbeat, and yellowing of the eyes or skin as pigment from broken-down hemoglobin accumulates. Dark urine, sometimes described as tea coloured or cola coloured, is a hallmark, and some people also report back or abdominal discomfort.
Studies indicate that these episodes are typically self-limited once the trigger is removed, because the youngest red cells carry enough enzyme to survive the challenge and the marrow steps up production 5. That does not make them trivial. The degree of red cell loss varies with the variant and the size of the exposure, and the drop can be substantial.
These symptoms are worth discussing with a clinician promptly rather than waiting to see what happens, particularly when dark urine, marked breathlessness or deepening jaundice appear together. Nobody should ignore an abnormal result or a new symptom on the assumption that it will resolve by itself.
A standard venous blood draw into an anticoagulated tube is all that is needed, and fasting is not usually required, though you should follow whatever instruction the ordering laboratory gives. Samples are temperature sensitive and enzyme activity falls in a poorly stored tube, so handling and transport time affect the result more than they do for many routine tests.
From there, the laboratory chooses a method. A fluorescent spot test is a widely used qualitative screen that reveals whether NADPH is being produced normally. A spectrophotometric assay measures the reaction rate and returns a quantitative value. Point-of-care devices also exist, and research suggests that the choice between qualitative and quantitative testing, along with the setting in which testing happens, strongly shapes which people get identified and how confidently intermediate results can be classified 7.
Timing is the other half of the method. Research suggests that testing is most reliable when the blood count has returned to baseline, well clear of an acute episode or a recent transfusion, because transfused and newly produced cells distort the measurement 6. If a result is borderline or conflicts with a clear clinical history, repeating it later is normal practice rather than a sign that something went wrong.
Yes, and the two answer different questions. The enzyme assay measures how much function your red cells currently have. Genetic testing identifies which variant of the G6PD gene you carry, which tells you about the underlying cause rather than today's activity level.
Genetic testing earns its place in two situations. The first is in females with intermediate enzyme results, where mosaicism blurs the activity measurement and identifying the variant adds clarity. The second is when the specific variant changes expectations, because the consequences of carrying a mild variant and a severe one are not the same. Studies indicate that variants differ substantially in the residual activity and stability of the enzyme they produce, which is what underlies classification into clinical classes 3, and research suggests that this biochemical variability explains why two people who share a diagnosis can have very different histories 2.
For most adults, the enzyme assay remains the practical starting point, with genetic testing reserved for cases where the functional result does not settle the question. Which route to take is a decision for the clinician ordering the work.
The enzyme value answers one question, and a handful of routine markers answer the rest. A complete blood count with hemoglobin shows whether red cell mass has actually fallen. A reticulocyte count shows whether the marrow is responding by pushing out young cells, which is the signature of recent red cell loss.
The breakdown markers fill in the picture. Bilirubin indirect rises as hemoglobin pigment is processed, which is what produces the visible yellowing during an episode. Lactate dehydrogenase rises when cells rupture and haptoglobin falls as it binds free hemoglobin. A peripheral blood smear can reveal the bite cells, blister cells and Heinz bodies that point toward oxidative injury rather than another cause of anemia.
Iron studies, vitamin B12 and folate are often added simply because anemia has several possible explanations and more than one can be present at once. A FitScript membership includes 150+ biomarkers tested per year, with results interpreted by Atlas, the AI health advisor, and any clinical decision made by a licensed provider.
Fava beans sit in a category of their own, and the rest of the diet is far less clear-cut than popular lists suggest. Research suggests that the evidence supports avoiding fava beans in people with this deficiency, while support for the long lists of other restricted foods circulating online is limited and inconsistent 8.
Legumes as a category are not the same as fava beans specifically, and treating them as interchangeable is not supported by what has been reported 8.
Sensitivity also varies between individuals and between variants, and reactions have been described from fresh, dried and in some reports processed fava preparations. If you carry a confirmed deficiency, the specific list of what to avoid is something to agree with your clinician rather than assemble from a search result. Nothing here is a dietary prescription.
Testing is usually considered when something in the history or the family tree raises the question. A relative with a known deficiency, a personal history of unexplained jaundice or anemia, an episode of dark urine after a meal or an illness, or anemia that nobody has been able to account for are all reasonable reasons to ask.
Ancestry is also part of the clinical picture. Research suggests that G6PD deficiency is most common in populations with historical exposure to malaria, which is why family origin is one of the first things a clinician asks about when the question comes up 1. Research suggests that testing is also used ahead of certain clinical decisions, where knowing enzyme status in advance changes what a provider will consider 7.
For people simply tracking their health data, the value of knowing is preventive rather than diagnostic. A documented result sitting in your record is useful on the day someone needs it, which is rarely the day you went looking for it.
For most adults, it looks almost exactly like life without one, with a few durable habits layered on. Knowing your status is the foundation. Keeping a written record, in a wallet, a phone health profile or both, means the information is available in an urgent care setting where no one has your history.
The second habit is disclosure. Telling every clinician, dentist and pharmacist about your G6PD status before anything new is started gives them the chance to factor it in while the decision is still open. The third is awareness during illness, since infection is a recognised precipitant of hemolysis in this condition 4, which means new breathlessness, deep fatigue or dark urine during an infection deserves a call rather than a wait.
No medicines, doses or supplement regimens are described here, and none should be started or stopped based on an article. Treatment decisions belong to a licensed provider who has reviewed your full picture.
Always, when a result is low, borderline or inconsistent with how you feel, and promptly when symptoms suggest active red cell breakdown. Dark urine, new or deepening jaundice, marked breathlessness, a racing heart or sudden collapse in exercise tolerance after a meal, an illness or a new medicine are reasons to seek care promptly rather than to monitor at home.
Outside of acute symptoms, a clinician is the right person to decide whether a borderline value needs repeating after recovery, whether genetic testing adds anything in your case, and which exposures are relevant to your particular variant. Please discuss your results and any treatment with a clinician or licensed provider, who can interpret them against your history rather than against a general article.
It checks how much glucose-6-phosphate dehydrogenase activity your red blood cells carry, which reflects how well they can withstand oxidative stress. Clinicians order it when someone has unexplained anemia or jaundice, a family history of the deficiency, or an episode of dark urine after a meal, an illness or a new medicine. A result is interpreted alongside your blood count and history, not on its own.
Fasting is not usually required for this particular measurement, but follow whatever instruction the ordering laboratory or clinician gives you, since other tests drawn in the same appointment may have their own requirements. The sample is a standard venous blood draw. Mention any recent illness, transfusion or episode of dark urine when you attend, because that information changes how the result is read.
Yes, and this is the most common reason a result misleads. During and shortly after an episode of red cell breakdown, the most affected cells have already been cleared and the bone marrow releases young cells with higher enzyme activity, which can push the average into the normal range. That is why repeat testing once your blood count is back to baseline is standard practice.
Yes. The gene sits on the X chromosome, so males who inherit an affected copy usually show clearly reduced activity, while females can show deficient, intermediate or near-normal activity depending on which copy is active in which cells. Intermediate results in females are the hardest to classify from an activity measurement alone, which is one reason a clinician may add genetic testing.
Turnaround depends on the laboratory, the method used and whether the sample has to be shipped, so ask the lab or ordering clinician for their current timeframe rather than relying on a general estimate. Qualitative screens are generally quicker to run than quantitative assays or genetic testing. Your clinician will tell you whether anything needs repeating once the result arrives.
No. The deficiency describes reduced enzyme activity inside red blood cells, which is a vulnerability rather than a blood count. Anemia is a low hemoglobin level, which may develop during an episode of red cell breakdown and then recover. Many people with reduced enzyme activity have completely normal blood counts most of the time.
Take it to a clinician rather than acting on it yourself. They will confirm the value, check the timing of the draw, look at your blood count and history, and decide whether repeat or genetic testing adds anything. They will also go through which exposures are relevant for you and make sure your status is recorded where other providers can see it.
No. Many people with reduced enzyme activity live without symptoms for years because nothing has stressed their red cells enough to matter. Episodes tend to follow a specific exposure such as fava beans, an infection or certain medicines, and severity varies widely between individuals. Knowing your status is mainly useful so that clinicians can factor it in before making decisions on your care.